[Illumi Medical Co., Ltd.] Illumi Medical was selected for the 2024 edition of Weekly Toyo Keizai’s “100 Amazing Ventures”
*Illumi Medical Co., Ltd.*
Press release: September 13, 2024
**
Illumi Medical was selected for the 2024 edition of Weekly Toyo Keizai’s “100 Amazing Ventures”
*Illumi Medical, which aims to realize minimally invasive phototherapy and photodiagnosis for cancer, Alzheimer’s disease, etc. by developing devices that can irradiate light from inside blood vessels to extravascular tissue, was selected as one of Weekly Toyo Keizai’s “Amazing Venture 100” 2024. Selected for the annual edition* Weekly Toyo Keizai September 21 and 28, 2024 Combined issue cover What are the amazing venture 100?
“100 Amazing Ventures” are 100 promising startups independently selected by Toyo Keizai Editorial Department. Every year, the Toyo Keizai Editorial Department carefully selects startups with unique business models and advanced technologies, taking into consideration factors such as the size of funding, in a special feature of Weekly Toyo Keizai.
・
Toyo Keizai “100 Amazing Ventures” 2024 Latest Edition/Full List https://toyokeizai.net/articles/-/824233
Today, the information is finally released! “Weekly Toyo Keizai” carefully selects 100 venture companies to watch in 2024! How to read “100 Amazing Ventures” taught by the editor-in-chief? !
Toyo Keizai Online will pre-announce “100 Venture Companies to Watch in 2024”! The future unicorn is inside!
*What is Illumi Medical*
An image of our technology that irradiates light into deep body tissues via blood vessels.
Image of light irradiation from inside a blood vessel to a target lesion in extravascular tissue
Illumi Medical (located in Nagoya City, Aichi Prefecture) is a venture from Nagoya University that develops the world’s first medical devices.
In recent years, catheter-based endovascular treatment technology has been used as a minimally invasive technique to diagnose and treat myocardial infarction and cerebral infarction, and the market is rapidly expanding on a global scale.
By applying this endovascular treatment technology, we have developed the world’s first device and system (ET-BLIT(R): * E*
ndovascular * T* therapy-* b* ased * L* ight * I* llumination * T* echnology, how to read:
We are proceeding with E.T.Brit). This development will expand the scope of application of phototherapy to diseases for which
phototherapy has not been possible until now, expand the potential and market of phototherapeutic drugs by expanding the areas of light irradiation, and improve effectiveness due to synergistic effects with DDS (drug delivery system). We are conducting research and development on phototherapeutic technology that improves treatment and reduces side effects, and selectively treats affected areas for various diseases.
We are currently conducting research and development in collaboration with a number of academia and operating companies to deepen elemental technologies, develop for clinical application, and expand
applications that utilize our platform technology as a foundation. Furthermore, we have received inquiries from a large number of business companies and academia.
Our company is developing “intravascular light irradiation technology” that will fundamentally change the light irradiation technology that has been a bottleneck in the clinical application of photomedicine. Through ET-BLIT(R), we will continue to conduct research and development in order to provide medical technology that contributes to extending healthy lifespans on a global scale.
Illumi Medical Company Profile
[Company name] Illumi Medical Co., Ltd.
[Capital] 180 million yen (including capital reserve)
[Representative] Representative Director, President and CEO Toshihiko Tsukamoto [Location] Creation Core Nagoya Room 203, 4-201 Sakurazaka,
Moriyama-ku, Nagoya, Aichi Prefecture
[Number of employees] 6 people (including 2 executives)
[Contact information regarding this matter] info@illumimedical.com